February 12, 2024
Reston, VA—Peptide receptor radionuclide therapy (PRRT) is effective for clinical control of symptomatic metastatic insulinomas, according to new research published in the February issue of The Journal of Nuclear Medicine. In the largest study to date of metastatic insulinoma patients treated with PRRT, more than 80 percent of patients had long-lasting symptom control, and nearly 60 percent were able to reduce the use of other drugs to treat the disease.
Metastatic insulinoma is a rare malignant neuroendocrine tumor characterized by inappropriate insulin secretion. This results in life-threatening hypoglycemia, which is often difficult to treat. The severity of symptoms can range from mild to life-threatening hypoglycemic events, leading to coma and death. Most insulinomas are benign, but approximately six percent -develop metastases and are therefore considered malignant.
“Because of the rarity of the disease, the treatment strategies for malignant metastatic disease are ill-defined,” stated Damian Wild, MD, PhD, nuclear medicine physician at University Hospital Basel, in Basel, Switzerland. “There is currently limited data available about the efficacy of PRRT in patients with malignant insulinomas. Our research aimed to evaluate whether PRRT could improve symptoms and if it had an impact on medication needed to control hypoglycemia.”
The retrospective study included 26 patients with malignant insulinomas who were treated with a total of 106 cycles of 90Y-DOTATOC or 177Lu-DOTATOC. A scoring system was used to quantify the severity and frequency of hypoglycemic episodes, and the score before and after PRRT was analyzed. Information on medication needed to control hypoglycemia before and after PRRT was also collected, an overall and progression-free survival was recorded.
PRRT was effective in controlling hypoglycemia in 81 percent of the study population and enabled 58 percent of patients to reduce the use of other drugs to control hypoglycemic episodes, resulting in reduced potential drug side effects. Overall and progression-free survival were 19.7 and 11.7 months, respectively.
“Compared to the effectiveness of other drugs commonly used to control hypoglycemia, the results of PRRT are promising and will likely have an impact on guidelines for the treatment of metastatic insulinoma,” noted Wild. “They also imply that PRRT is indicated at an earlier time point, for example as a first or second line of therapy, for the treatment of metastatic insulinomas.”
|Figure 3. 62-year-old female patient who received 3 [90Y]Y-DOTATOC and 1 [177Lu]Lu-DOTATOC therapy cycles (total activity, 26.7 GBq) and benefited more than 15 of 18 months of observation. Baseline CT scan (A) and intratherapeutic [90Y]Y-DOTATOC SPECT/CT of second therapy cycle show multiple liver metastases (B). CT scan after second therapy cycle shows partial tumor response with significantly reduced tumor burden according to RECIST 1.1 (C). Intratherapeutic [90Y]Y-DOTATOC SPECT/CT of fourth therapy cycle (D) shows reduced [90Y]Y-DOTATOC uptake in liver metastases compared with [90Y]Y-DOTATOC SPECT/CT of second therapy cycle (B), which also indicates treatment response.
The authors of “Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis” include Liene Friebe, Martin Braun, and Andreas Baumann, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland; Martin T. Freitag, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland, ENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland, and Clinic of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany; Guillaume Nicolas and Damian Wild, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland and ENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland; David Bushnell, Division of Nuclear Medicine, Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, Iowa; and Emanuel Christ, ENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland and Department of Endocrinology, Diabetology, and Metabolism, University Hospital Basel, Basel, Switzerland.
Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or email@example.com.
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed more than 16 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.